ISI Acquires Apyx, Inc. to Cement Leadership in Life Sciences Regulatory Consulting, Services and Software
WHIPPANY, N.J.
ISI, a provider of software and services for the life sciences industry, announced that it has acquired Apyx, Inc. The merger adds to ISI’s growing professional services business and enhances the company’s range of offerings in submissions management and outsourcing. The two companies’ shared commitment to customer service and responsiveness make the merger a fit.
ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing, repeat services. Over the last decade, the company has helped biopharmaceutical companies all over the world bring dozens of therapies through regulatory approval to patients in need. The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services that respond to today’s complex submission environment.
“With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe," said Ken VanLuvanee, CEO, President and Founder of Apyx, Inc.
ISI makes the acquisition at a time of flux for the pharmaceutical industry. In the wake of transformational new regulations and a host of economic and competitive factors, life sciences firms are dealing with a complex global marketplace they have never seen before. Diverse and ever-changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of unparalleled complexity.
With the acquisition of Apyx, ISI will deliver more efficient and standardized processes and systems, enable operational alignment around the globe, and facilitate a more effective exchange of information to help clients navigate these new challenges.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
